Can Europe Finance and Keep Its Biotech Winners?

Why It Matters

Without deeper capital pools and streamlined regulations, Europe risks squandering its scientific edge, limiting the continent’s ability to produce globally competitive biotech champions.

Key Takeaways

• US biotech IPOs raised >$1B in early 2026, showing market vigor
• 66 of 67 EU biotech IPOs listed outside Europe, highlighting financing gap
• European life sciences VC represents 7% of global market, vs 63% US
• ELSC controls €24B (~$26B) assets, backing 1,400 firms to accelerate growth
• Proposals call for EU fund‑of‑funds and a biotech‑focused stock exchange

Pulse Analysis

The early‑2026 wave of U.S. life‑sciences IPOs, highlighted by six successful offerings and a direct listing that together pulled in more than $1 billion, illustrates the depth of capital available when market structures align with scientific ambition. By contrast, Europe’s biotech sector, despite producing world‑class research, has struggled to attract comparable financing, with 66 of 67 EU‑based companies opting for foreign exchanges. This disparity stems from a fragmented capital market, limited venture‑capital depth, and pension‑fund allocations that hover around 0.02% of assets, far below the roughly 2% seen in the United States.

The European Life Sciences Coalition (ELSC) seeks to reverse this trend. Backed by investors managing roughly €24 billion (about $26 billion) and supporting over 1,400 companies, the coalition is not an investment fund but a policy engine. Its agenda focuses on engaging institutional investors—pension funds, insurers, banks—to raise life‑sciences venture allocations, while lobbying EU regulators for a more integrated capital market, streamlined approval pathways, and a dedicated biotech exchange that can shepherd companies from IPO through scale.

If Europe can implement these reforms, the continent could retain its scientific talent and translate breakthroughs into market‑ready therapies. A coordinated fund‑of‑funds structure, mandatory minimum VC exposure for large institutional portfolios, and a unified exchange would deepen liquidity and reduce regulatory friction. Such changes would not merely emulate the U.S. model but create a uniquely European financing ecosystem, ensuring that groundbreaking research stays at home and fuels the next generation of global biotech leaders.